Sandberg, Lovisa http://orcid.org/0000-0001-6982-5244
Taavola, Henric http://orcid.org/0000-0002-2604-2810
Aoki, Yasunori http://orcid.org/0000-0002-5881-2023
Chandler, Rebecca http://orcid.org/0000-0002-9334-9046
Norén, G. Niklas http://orcid.org/0000-0002-4595-230X
Article History
First Online: 20 June 2020
Compliance with Ethical Standards
:
: No funding to conduct the study was received.
: Lovisa Sandberg, Henric Taavola, Rebecca Chandler, Yasunori Aoki, and G. Niklas Norén have no conflicts of interest that are directly relevant to the content of this study. As of October 2018, Yasunori Aoki is a full-time employee of Astra Zeneca. However, all of his contributions to this work were made prior to the time of departure, as part of his employment at UMC.
: The datasets generated and analysed during the current study are not publicly available due to agreements between contributors of data to the database used (VigiBase) and the custodian of this database. National centres (mainly national drug regulatory authorities) constituting the WHO Programme for International Drug Monitoring (PIDM) contribute data to VigiBase, and UMC is the custodian in its capacity as a WHO collaborating centre for international drug monitoring.